搜尋
Yahoo! 財經
你好!Guest
[ 用戶登入新用戶? ]

Savient Pharmaceuticals, Inc.
(SVNT)

Up 0.36 (2.89%)
12.810
最新價
2010年2月10日 上午 5:00 HKT
買入: N/A昨日收市: N/A
賣出: N/A開市: N/A
今日波幅: N/A

基本資料

其他股份的基本資料:
Savient Pharmaceuticals, Inc.
One Tower Center
Fourteenth Floor
East Brunswick, NJ 08816
Phone: 732-418-9300
Fax: 732-418-0570
Web Site: http://www.savientpharma.com

 DETAILS 
Index Membership:S&P 600 SmallCap
S&P 1500 Super Comp
Sector:Healthcare
Industry:Biotechnology
Employees (last reported count):73

 REUTERS ABRIDGED BUSINESS SUMMARY 
Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing, manufacturing, and marketing pharmaceutical products that target unmet medical needs. The company sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It distributes the branded version of oxandrolone in the United States, under the name Oxandrin and authorized generic version of oxandrolone through an agreement with Watson Pharma, Inc. The company also involves in developing KRYSTEXXA (pegloticase), a biologic PEGylated uricase enzyme to control hyperuricemia, and to manage signs and symptoms of gout, including the improvement of tophi, improvement in chronic pain, improved physical functioning, and decreased frequency of flares for patients with treatment-failure gout. It distributes its products through wholesalers. The company, formerly known as Bio-Technology General Corp., was founded in 1980 and is headquartered in East Brunswick, New Jersey.
Key Statistics
More from Reuters
Expanded Business Description

 COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Savient Pharmaceuticals, Inc.


    More from Reuters
    Reuters offers more in-depth Company Research , Stock Screening , and >Risk Alerts on over 10,000 U.S. Equities.

     REUTERS ABRIDGED FINANCIAL SUMMARY 
    View Financials
    More from Reuters
    Significant Developments - Highlights - Performance - Ratio Comparison


     OFFICERS 
     PayExercised
    Mr. Paul R. Hamelin R.Ph., 55
    Pres
    $ 344.00K $ 276.00K
    Mr. Philip K. Yachmetz J.D, 53
    Sr. VP, Sec. and Gen. Counsel
    $ 388.00K $ 520.00K
    Mr. David G. Gionco ,
    Chief Financial Officer, VP and Treasurer
    N/A N/A
    Mr. Peter Clarke Ph.D., 50
    VP of Manufacturing
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders
    More from Reuters:
    Full List - Bios - Compensation - Options


    加進我的投資組合 加進我的投資組合    寄給朋友 寄給朋友

    資料提供及版權歸於 AASTOCKSDBPower經濟通內幕人 Insiders.hkInteractive Data Real Time Services凱基証券QuamnetTelekurs (USA) INC
    用戶意見 | 私隱政策 | 服務條款 | 免責條款
    Copyright © 2010 Yahoo! Hong Kong Limited. All rights reserved. 版權所有 不得轉載
    免責聲明:以上資料由雅虎香港有限公司的資料提供夥伴(如AASTOCKS、DBPower、經濟通、內幕人Insiders.hk、Interactive Data Real Time Services、凱基証券、Quamnet 和 Telekurs (USA) INC)提供,僅作參考之用,雅虎香港有限公司及資料提供夥伴對以上資訊的準性和可靠性不能亦不會作任何保證或承擔,並對基於該等資料或有關的錯漏或延誤而作出的任何決定或導致的損失概不負責。
    權益披露包括: 法團大股東之交易, 個人大股東之交易, 董事或最高行政人員之交易,及董事或最高行政人員買賣其上市公司的子公司或付屬公司之交易。
    所有股票報價及認股證報價均延遲最少十五分鐘。